Autolus Therapeutics Files Routine 8-K on Jan 26

TL;DR

**Autolus Therapeutics filed a routine 8-K, no major news.**

AI Summary

Autolus Therapeutics plc filed an 8-K on January 26, 2024, reporting an event that occurred on January 22, 2024. This filing is a routine update under Regulation FD Disclosure and Financial Statements and Exhibits, indicating no major new financial or operational news. For investors, this means there's no immediate significant positive or negative catalyst disclosed in this specific filing that would drastically alter the stock's outlook, suggesting a period of stability or continued focus on existing developments.

Why It Matters

This filing is a standard procedural update, indicating no new material information that would immediately impact Autolus Therapeutics' stock price or investor sentiment. It's important for transparency but doesn't signal a change in the company's trajectory.

Risk Assessment

Risk Level: low — This 8-K is a standard disclosure with no new material information, posing minimal risk to investors.

Analyst Insight

A smart investor would view this filing as a non-event, confirming business as usual, and would continue to monitor for more substantive news like clinical trial results or financial reports.

Key Numbers

• $0.000042 — Par value per ordinary share (This is the nominal value of each ordinary share of Autolus Therapeutics plc.)

Key Players & Entities

• Autolus Therapeutics plc (company) — the registrant filing the 8-K
• The Nasdaq Global Select Market (company) — exchange where Autolus Therapeutics' shares are registered
• $0.000042 (dollar_amount) — par value per ordinary share

Forward-Looking Statements

• Autolus Therapeutics plc will continue to file routine disclosures without significant new material information in the near term. (Autolus Therapeutics plc) — high confidence, target: Q1 2024

FAQ

From the Filing

0001730463-24-000007.txt : 20240126 0001730463-24-000007.hdr.sgml : 20240126 20240126130213 ACCESSION NUMBER: 0001730463-24-000007 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240122 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240126 DATE AS OF CHANGE: 20240126 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 24566314 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 8-K 1 autl-20240122.htm 8-K autl-20240122 0001730463 FALSE 0001730463 2024-01-22 2024-01-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) The Mediaworks 191 Wood Lane London W12 7FP United Kingdom (Address of principal executive offices)(Zip Code) (44) 20 3829 6230 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, par value $0.000042 per share AUTL The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 7.01 Regulation FD Disclosure On January 22, 2024, Autolus Therapeutics plc issued a press release announcing the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for obecabtagene autoleucel (obe-cel) for patients with relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of November 16, 2024, a standard review timeline consistent with recently approved CAR T therapies. The information contained in the presentation is furnished as Exhibit 99.1 and shall not be deemed “fi